A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors

PURPOSE: Tolerability, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of carfilzomib, a selective proteasome inhibitor, administered twice weekly by 2–10-min intravenous (IV) infusion on days 1, 2, 8, 9, 15, and 16 in 28-day cycles, were assessed in patients with advanced solid tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Papadopoulos, Kyriakos P., Burris, Howard A., Gordon, Michael, Lee, Peter, Sausville, Edward A., Rosen, Peter J., Patnaik, Amita, Cutler, Richard E., Wang, Zhengping, Lee, Susan, Jones, Suzanne F., Infante, Jeffery R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784064/
https://www.ncbi.nlm.nih.gov/pubmed/23975329
http://dx.doi.org/10.1007/s00280-013-2267-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784064/
https://www.ncbi.nlm.nih.gov/pubmed/23975329
http://dx.doi.org/10.1007/s00280-013-2267-x

Ejemplares similares